By proceeding, you agree to our Terms of Use and Privacy Policy.
Dr. Lau received her Ph.D. from the University of Sydney, Australia, where her research focused on the development of novel diagnostic platforms for the diagnosis of invasive fungal diseases. She completed her CPEP Clinical Microbiology Fellowship training at the NIH Clinical Center and is board-certified through the American Board of Medical Microbiology.In 2013, she joined the Microbiology Faculty in the Department of Laboratory Medicine (DLM) at the NIH Clinical Center, where she co-directed the Bacteriology, Specimen Processing, Parasitology, and Molecular Epidemiology sections. In 2018, Dr. Lau was promoted to Chief of the Sterility Testing Service in DLM to support the NIH-wide cGMP aseptic processing and manufacturing of cellular therapy and drug pharmaceuticals for NIH clinical protocols.Dr. Lau's translational research focus on the development of new rapid diagnostic platforms for microbial identification and the detection of resistance mechanisms using molecular-based techniques and mass spectrometry. In 2014, Dr. Lau was recognized with the prestigious Forbes 30 Under 30 award in Science and Healthcare for her development of the NIH Mold MALDI-TOF MS Database.
Talks About #microbiology #clinical #drugpharmaceutical
Preferred Locations #NorthAmerica